Posterior reversible encephalopathy syndrome in pediatric patients: pathophysiology, diagnosis, and management

References

• Anastasopoulou S, Eriksson MA, Heyman M, et al. Posterior reversible encephalopathy syndrome in children with acute lymphoblastic leukemia: clinical characteristics, risk factors, course, and outcome of disease. Pediatr Blood Cancer. 2019;66(5):e27594.
   PubMed Web of Science ®Google Scholar
• Arzanian MT, Shamsian BS, Karimzadeh P, et al. Posterior reversible encephalopathy syndrome in pediatric hematologic-oncologic disease: literature review and case presentation. Iran J Child Neurol. 2014;8(2):1–10.
   PubMedGoogle Scholar
• Gaziev J, Marziali S, Paciaroni K, et al. Posterior reversible encephalopathy syndrome after hematopoietic cell transplantation in children with hemoglobinopathies. Biol Blood Marrow Transplant. 2017;23(9):1531–1540.
   PubMed Web of Science ®Google Scholar
• Gavrilovici C, Miron I, Voroneanu L, et al. Posterior reversible encephalopathy syndrome in children with kidney disease. Int Urol Nephrol. 2017;49(10):1793–1800.
   PubMed Web of Science ®Google Scholar
• Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334:494–500.
   PubMed Web of Science ®Google Scholar
• Hurwitz RL, Mahoney DH Jr, Armstrong DL, et al. Reversible encephalopathy and seizures as a result of conventional vincristine administration. Med Pediatr Oncol. 1988;16:216–219.
   PubMedGoogle Scholar
• Pihko H, Tyni T, Virkola K, et al. Transient ischemic cerebral lesions during induction chemotherapy for acute lymphoblastic leukemia. J Pediatr. 1993;123:718–724.
   PubMed Web of Science ®Google Scholar
• Lucchini G, Grioni D, Colombini A, et al. Encephalopathy syndrome in children with hemato-oncological disorders is not always posterior and reversible. Pediatr Blood Cancer. 2008;51:629–633.
   PubMed Web of Science ®Google Scholar
• Cooney MJ, Bradley WG, Symko SC, et al. Hypertensive encephalopathy: complication in children treated for myeloproliferative disorders-report of three cases. Radiology. 2000;214:711–716.
   PubMed Web of Science ®Google Scholar
• Kwon S, Koo J, Lee S. Clinical spectrum of reversible posterior leukoencephalopathy syndrome. Pediatr Neurol. 2001;24:361–364.
   PubMed Web of Science ®Google Scholar
• Norman JK, Parke JT, Wilson DA, et al. Reversible posterior leukoencephalopathy syndrome in children undergoing induction therapy for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2007;49:198–203.
   PubMed Web of Science ®Google Scholar
• Rathi B, Azad RK, Vasudha N, et al. Asparaginase-induced reversible posterior leukoencephalopathy syndrome in a child with acute lymphoblastic leukemia. Pediatr Neurosurg. 2002;37:203–205.
   PubMed Web of Science ®Google Scholar
• D'Angelo P, Farruggia P, Lo bello A, et al. Reversible posterior leukoencephalopathy syndrome: report of 2 simultaneous cases in children. J Pediatr Hematol Oncol. 2006;28:177–181.
   PubMed Web of Science ®Google Scholar
• Gupta A, Swaroop C, Rastogi R, et al. Simultaneous occurrence of posterior reversible leukoencephalopathy syndrome in two cases of childhood acute lymphoblastic leukemia induction chemotherapy. Pediatr Hematol Oncol. 2008;25:351–358.
   PubMed Web of Science ®Google Scholar
• Hourani R, Abboud M, Hourani M, et al. asparaginase-induced posterior reversible encephalopathy syndrome during acute lymphoblastic leukemia treatment in children. Neuropediatrics. 2008;39:46–50.
   PubMed Web of Science ®Google Scholar
• Morris EB, Laningham FH, Sandlund JT, et al. Posterior reversible encephalopathy syndrome in children with cancer. Pediatr Blood Cancer. 2007;48:152–159.
   PubMed Web of Science ®Google Scholar
• Niyadurupola N, Burnett CA, Allen LE. Reversible posterior leucoencephalopathy syndrome: a cause of temporary cortical blindness. Br J Ophthalmol. 2005;89:924–925.
   PubMed Web of Science ®Google Scholar
• Shin RK, Stern JW, Janss AJ, et al. Reversible posterior leukoencephalopathy during the treatment of acute lymphoblastic leukemia. Neurology. 2001;56:388–391.
   PubMed Web of Science ®Google Scholar
• Bartynski WS. Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema. AJNR Am J Neuroradiol. 2008;29:1043–1049.
   PubMed Web of Science ®Google Scholar
• San martín garcía I, Urabayen alberdi R, Díez bayona V, et al. [Posterior reversible encephalopathy syndrome: 5 chemotherapy related cases]. An Pediatr (Barc). 2014;80:117–121. Spanish.
   PubMed Web of Science ®Google Scholar
• Lewis MB. Cyclosporin neurotoxicity after chemotherapy: cyclosporin causes reversible posterior leukoencephalopathy syndrome. BMJ. 1999;319:54–55.
   PubMedGoogle Scholar
• Kur JK, Esdaile JM. Posterior reversible encephalopathy syndrome: an underrecognized manifestation of systemic lupus erythematosus. J Rheumatol. 2006;33:2178–2183.
   PubMed Web of Science ®Google Scholar
• Koch S, Rabinstein A, Falcone S, et al. Diffusion-weighted imaging shows cytotoxic and vasogenic edema in eclampsia. AJNR Am J Neuroradiol. 2001;22:1068–1070.
   PubMed Web of Science ®Google Scholar
• Bartynski WS, Boardman JF, Zeigler ZR, et al. Posterior reversible encephalopathy syndrome in infection, sepsis, and shock. AJNR Am J Neuroradiol. 2006;27:2179–2190.
   PubMed Web of Science ®Google Scholar
• Pavlakis SG, Frank Y, Chusid R. Hypertensive encephalopathy, reversible occipitoparietal encephalopathy, or reversible posterior leukoencephalopathy: three names for an old syndrome. J Child Neurol. 1999;14:277–281.
   PubMed Web of Science ®Google Scholar
• Wong R, Beguelin GZ, De LIMA M, et al. Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2003;122:128–134.
   PubMed Web of Science ®Google Scholar
• Ito Y, Arahata Y, Goto Y, et al. Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome. AJNR Am J Neuroradiol. 1998;19:415–417.
   PubMed Web of Science ®Google Scholar
• Sanchez-Carpintero R, Narbona J, Lopez de Mesa R, et al. Transient posterior encephalopathy induced by chemotherapy in children. Pediatr Neurol. 2001;24:145–148.
   PubMed Web of Science ®Google Scholar
• Hualde olascoaga J, Molins castiella T, Souto hernández S, et al. [Reversible posterior leukoencephalopathy: report of two cases after vincristine treatment]. An Pediatr (Barc). 2008;68:282–285. Spanish.
   PubMedGoogle Scholar
• Ocaña rico M, Javier manchón G, Coroleu lletget W, et al. [Reversible posterior encefalopathy syndrome during induction chemoterapy for acute lymphoblastic leukemia]. Med Clin (Barc). 2002;119:795–796. Spanish.
   PubMed Web of Science ®Google Scholar
• Kridis WB, Mdhaffer M, Hentati Y, et al. Posterior reversible encephalopathy syndrome in leukemic children: a sensitive issue. Curr Drug Safe. 2015;10:180–183.
   PubMed Web of Science ®Google Scholar
• Bartynski WS, Tan HP, Boardman JF, et al. Posterior reversible encephalopathy syndrome after solid organ transplantation. AJNR Am J Neuroradiol. 2008;29:924–930.
   PubMed Web of Science ®Google Scholar
• Millichap JG. Posterior reversible encephalopathy syndrome in ALL. Pediatr Neurol Briefs. 2015;29:56.
   Google Scholar
• Yasuhara T, Tokunaga K, Hishikawa T, et al. Posterior reversible encephalopathy syndrome. J Clin Neurosci. 2011;18:406–409.
   Google Scholar
• Kanekiyo T, Hara J, Matsuda-Hashii Y, et al. Tacrolimus-related encephalopathy following allogeneic stem cell transplantation in children. Int J Hematol. 2005;81:264–268.
   PubMed Web of Science ®Google Scholar
• Stott VL, Hurrell MA, Anderson TJ. Reversible posterior leukoencephalopathy syndrome: a misnomer reviewed. Intern Med J. 2005;35:83–90.
   PubMed Web of Science ®Google Scholar
• Dicuonzo F, Salvati A, Palma M, et al. Posterior reversible encephalopathy syndrome associated with methotrexate neurotoxicity: conventional magnetic resonance and diffusion-weighted imaging findings. J Child Neurol. 2009;24:1013–1018.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Im SA, Lee JW, et al. Predisposing factors of posterior reversible encephalopathy syndrome in acute childhood leukemia. Pediatr Neurol. 2012;47:436–442.
   PubMed Web of Science ®Google Scholar
• Panis B, Vlaar AM, Van well GT, et al. Posterior reversible encephalopathy syndrome in paediatric leukaemia. Eur J Paediatr Neurol. 2010;14:539–545.
   PubMed Web of Science ®Google Scholar
• Shimizu Y, Tha KK, Iguchi A, et al. Isolated posterior fossa involvement in posterior reversible encephalopathy syndrome. Neuroradiol J. 2013;26(5):514–519.
   PubMedGoogle Scholar
• Bartynski WS, Zeigler Z, Spearman MP, et al. Etiology of cortical and white matter lesions in cyclosporin-A and FK-506 neurotoxicity. AJNR Am J Neuroradiol. 2001;22:1901–1914.
   PubMed Web of Science ®Google Scholar
• Jarosz JM, Howlett DC, Cox TC, et al. Cyclosporine-related reversible posterior leukoencephalopathy: MRI. Neuroradiology. 1997;39:711–715.
   PubMed Web of Science ®Google Scholar
• Reinohs M, Straube T, Baum P, et al. Recurrent reversible cerebral edema after long term immunosuppression with tacrolimus. J Neurol. 2002;249:780–781.
   PubMed Web of Science ®Google Scholar
• Bartynski WS, Zeigler ZR, Shadduck RK, et al. Pretransplantation conditioning influence on the occurrence of cyclosporine or FK-506 neurotoxicity in allogeneic bone marrow transplantation. AJNR Am J Neuroradiol. 2004;25:261–269.
   PubMed Web of Science ®Google Scholar
• Minn AY, Fisher PG, Barnes PD, et al. A syndrome of irreversible leukoencephalopathy following pediatric allogeneic bone marrow transplantation. Pediatr Blood Cancer. 2007;48:213–217.
   PubMed Web of Science ®Google Scholar
• Siegal D, Keller A, Xu W, et al. Central nervous system complications after allogeneic hematopoietic stem cell transplantation: incidence, manifestations, and clinical significance. Biol Blood Marrow Transplant. 2007;13:1369–1379.
   PubMed Web of Science ®Google Scholar
• Uckan D, Cetin M, Yigitkanli I, et al. Life-threatening neurological complications after bone marrow transplantation in children. Bone Marrow Transplant. 2005;35:71–76.
   PubMed Web of Science ®Google Scholar
• Erer B, Polchi P, Lucarelli G, et al. CsA-associated neurotoxicity and ineffective prophylaxis with clonazepam in patients transplanted for thalassemia major: analysis of risk factors. Bone Marrow Transplant. 1996;18:157–162.
   PubMed Web of Science ®Google Scholar
• Tam CS, Galanos J, Seymour JF, et al. Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic malignancies. Am J Hematol. 2004;77:72–76.
   PubMed Web of Science ®Google Scholar
• Titos-arcos JC, León-villar J, Amigo-lozano ML, et al. [Posterior reversible leukoencephalopathy syndrome induced by L-asparaginase in a teenage female diagnosed with acute lymphoblastic leukemia]. Rev Neurol. 2011;52:58–60. Spanish.
   PubMed Web of Science ®Google Scholar
• Kieslich M, Porto L, Lanfermann H, et al. Cerebrovascular complications of L-asparaginase in the therapy of acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2003;25:484–487.
   PubMed Web of Science ®Google Scholar
• Pound CM, Keene DL, Udjus K, et al. Acute encephalopathy and cerebral vasospasm after multiagent chemotherapy including PEG-asparaginase and intrathecal cytarabine for the treatment of acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2007;29:183–186.
   PubMed Web of Science ®Google Scholar
• Paulson OB, Strandgaard S, Edvinsson L. Cerebral autoregulation. Cerebrovasc Brain Metab Rev. 1990;2(2):161–192.
   PubMedGoogle Scholar
• Ulrich PT, Becker T, Kempski OS. Correlation of cerebral blood flow and MCA flow velocity measured in healthy volunteers during acetazolamide and CO2 stimulation. J Neurol Sci. 1995;129(2):120–130.
   PubMed Web of Science ®Google Scholar
• Fortune JB, Feustel PJ, deLuna C, et al. Cerebral blood flow and blood volume in response to O2 and CO2 changes in normal humans. J Trauma. 1995;39(3):463–471; discussion471–472.
   PubMedGoogle Scholar
• Mukherjee P, McKinstry RC. Reversible posterior leukoencephalopathy syndrome: evaluation with diffusion-tensor MR imaging. Radiology. 2001;219:756–765.
   PubMed Web of Science ®Google Scholar
• Bartynski WS. Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features. AJNR Am J Neuroradiol. 2008;29:1036–1042.
   PubMed Web of Science ®Google Scholar
• Casey SO, Sampaio RC, Michel E, et al. Posterior reversible encephalopathy syndrome: utility of fluid-attenuated inversion recovery MR imaging in the detection of cortical and subcortical lesions. AJNR Am J Neuroradiol. 2000;21:1199–1206.
   PubMed Web of Science ®Google Scholar
• Eguchi K, Kasahara K, Nagashima A, et al. Two cases of malignant hypertension with reversible diffuse leukoencephalopathy exhibiting a reversible nocturnal blood pressure “riser” pattern. Hypertens Res. 2002;25:467–473.
   PubMed Web of Science ®Google Scholar
• Garg RK. Posterior leukoencephalopathy syndrome. Postgrad Med J. 2001;77:24–28.
   PubMed Web of Science ®Google Scholar
• Belaramani KM, Lai V, Li CH, et al. Reversible posterior leukoencephalopathy syndrome in Chinese children induced by chemotherapy: a review of five cases. Hong Kong Med J. 2011;17:61–66.
   PubMedGoogle Scholar
• Ozcakar ZB, Ekim M, Fitoz S, et al. Hypertension induced reversible posterior leukoencephalopathy syndrome: a report of two cases. Eur J Pediatr. 2004;163:728–730.
   PubMed Web of Science ®Google Scholar
• Prasad N, Gulati S, Gupta RK, et al. Is reversible posterior leukoencephalopathy with severe hypertension completely reversible in all patients? Pediatr Nephrol. 2003;18:1161–1166.
   PubMed Web of Science ®Google Scholar
• Singhi P, Subramanian C, Jain V, et al. Reversible brain lesions in childhood hypertension. Acta Paediatr. 2002;91:1005–1007.
   PubMed Web of Science ®Google Scholar
• Karakis I, MacDonald JA, Stefanidou M, et al. Clinical and radiological features of brainstem variant of hypertensive encephalopathy. J Vasc Interv Neurol. 2009;2:172–176.
   PubMedGoogle Scholar
• Ay H, Buonanno FS, Schaefer PW, et al. Posterior leukoencephalopathy without severe hypertension: utility of diffusion-weighted MRI. Neurology. 1998;51:1369.
   PubMed Web of Science ®Google Scholar
• Vaughn DJ, Jarvic JG, Hackney D, et al. High-dose cytarabine neurotoxicity: MR findings during the acute phase. Am J Neuroradiol. 1993;14:1014–1016.
   PubMed Web of Science ®Google Scholar
• Aradillas E, Arora R, Gasperino J. Methotrexate-induced posterior reversible encephalopathy syndrome. J Clin Pharm Ther. 2011;36:529–536.
   PubMed Web of Science ®Google Scholar
• Feinberg WM, Swenson MR. Cerebrovascular complications of L-asparaginase therapy. Neurology. 1988;38:127–133.
   PubMed Web of Science ®Google Scholar
• Inaba H, Khan RB, Laningham FH, et al. Clinical and radiological characteristics of methotrexate-induced acute encephalopathy in pediatric patients with cancer. Ann Oncol. 2008;19:178–184.
   PubMed Web of Science ®Google Scholar
• Miese FR, Schuster FR, Pierstorff K, et al. Magnetization transfer imaging provides no evidence of demyelination in methotrexate induced encephalopathy. AJNR Am J Neuroradiol. 2011;32:E110.
   PubMedGoogle Scholar
• Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol. 2002;249:9–17.
   PubMed Web of Science ®Google Scholar
• Alehan F, Erol I, Agildere AM, et al. Posterior leukoencephalopathy syndrome in children and adolescents. J Child Neurol. 2007;22:406–413.
   PubMed Web of Science ®Google Scholar
• Suminoe A, Matsuzaki A, Kira R, et al. Reversible posterior leukoencephalopathy syndrome in children with cancers. J Pediatr Hematol Oncol. 2003;25:236–239.
   PubMed Web of Science ®Google Scholar
• Kastrup O, Maschke M, Wanke I, et al. Posterior reversible encephalopathy syndrome due to severe hypercalcemia. J Neurol. 2002;249:1563–1566.
   PubMed Web of Science ®Google Scholar
• Parasole R, Petruzziello F, Menna G, et al. Central nervous system complications during treatment of acute lymphoblastic leukemia in a single pediatric institution. Leuk Lymphoma. 2010;51:1063–1071.
   PubMed Web of Science ®Google Scholar
• Fukuyama T, Tanaka M, Nakazawa Y, et al. Prophylactic treatment for hypertension and seizure in a case of allogeneic hematopoietic stem cell transplantation after posterior reversible encephalopathy syndrome. Pediatr Transplant. 2011;15:E169–E173.
   PubMed Web of Science ®Google Scholar
• Antunes NL, Small TN, George D, et al. Posterior leukoencephalopathy syndrome may not be reversible. Pediatr Neurol. 1999;20:241–243.
   PubMed Web of Science ®Google Scholar
• Sweany JM, Bartynski WS, Boardman JF. “Recurrent” posterior reversible encephalopathy syndrome: report of three cases PRES can strike twice! J Comput Assist Tomogr. 2007;31:148–156.
   PubMed Web of Science ®Google Scholar
• Dawson DG, Trobe JD. Blindness after liver transplant. Surv Ophthalmol. 2002;47:387–391.
   PubMed Web of Science ®Google Scholar
• Tallaksen CM, Kerty E, Bakke S. Visual hallucinations in a case of reversible hypertension-induced brain oedema. Eur J Neurol. 1998;5:615–618.
   PubMed Web of Science ®Google Scholar
• Woodard P, Helton K, McDaniel H, et al. Encephalopathy in pediatric patients after allogeneic hematopoietic stem cell transplantation is associated with a poor prognosis. Bone Marrow Transplant. 2004;33:1151–1157.
   PubMed Web of Science ®Google Scholar
• Ergün T, Lakadamyali H, Yilmaz A. Recurrent posterior reversible encephalopathy syndrome in a hypertensive patient with end-stage renal disease. Diagn Interv Radiol. 2008;14:182–185.
   PubMed Web of Science ®Google Scholar
• Thaipisuttikul I, Phanthumchinda K. Recurrent reversible posterior leukoencephalopathy in a patient with systemic lupus erythematosus. J Neurol. 2005;252:230–231.
   PubMed Web of Science ®Google Scholar
• Finsterer J, Stollberger C, Ostermann E, et al. Recurrent posterior reversible encephalopathy syndrome in mitochondrial disorder. Blood Press. 2009;12:1–4.
   Google Scholar
• Baytan B, Evim MS, Güler S, et al. Acute central nervous system complications in pediatric acute lymphoblastic leukemia. Pediatr Neurol. 2015;53:312–318.
   PubMed Web of Science ®Google Scholar
• Umeda K, Yoshida M, Suzuki N, et al. [Complications in the central nervous system during chemotherapy for childhood acute lymphoblastic leukemia: JACLS ALL-02 study]. Rinsho Ketsueki. 2007;48:204–211. Japanese.
   PubMedGoogle Scholar
• McKinney AM, Short J, Truwit CL, et al. Posterior reversible encephalopathy syndrome: incidence of atypical regions of involvement and imaging findings. Am J Roentgenol. 2007;189:904–912.
   PubMed Web of Science ®Google Scholar
• Covarrubias DJ, Luetmer PH, Campeau NG. Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion-weighted MR images. AJNR Am J Neuroradiol. 2002;23:1038–1048.
   PubMed Web of Science ®Google Scholar
• Ahn KJ, You WJ, Jeong SL, et al. Atypical manifestations of reversible posterior leukoencephalopathy syndrome: findings on diffusion imaging and ADC mapping. Neuroradiology. 2004;46:978–983.
   PubMed Web of Science ®Google Scholar
• Keyserling HF, Provenzale JM. Atypical imaging findings in a near-fatal case of posterior reversible encephalopathy syndrome in a child. Am J Roentgenol. 2007;188:219–221.
   PubMed Web of Science ®Google Scholar
• Kumar A, Keyrouz SG, Willie JT, et al. Reversible obstructive hydrocephalus from hypertensive encephalopathy. Neurocrit Care. 2012;16:433–439.
   PubMed Web of Science ®Google Scholar
• Bechstein WO. Neurotoxicity of calcineurin inhibitors impact and clinical management. Transplant Int. 2000;13:313–326.
   PubMed Web of Science ®Google Scholar